Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients An Exploratory Single-Arm Phase II Clinical Trail
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Antineoplastics (Primary) ; Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 21 Sep 2018 New trial record